BRAF in early stage melanoma: rationale for testing and treatment?

E-ISSN： 1365-2133|173|1|9-10

ISSN： 0007-0963

Source： BRITISH JOURNAL OF DERMATOLOGY, Vol.173, Iss.1, 2015-07, pp. : 9-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metastatic Melanoma: Scientific Rationale for Sorafenib Treatment and Clinical Results

Oncology Research and Treatment, Vol. 31, Iss. 7, 2008-06 ,pp. : 398-403

Karger

Access to resources Recommend Favorite

Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1617-1619

John Wiley & Sons Inc

Access to resources Recommend Favorite

Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of 18F‐FDG‐PET and 18F‐FLT‐PET

CONTRAST MEDIA & MOLECULAR IMAGING (ELECTRONIC), Vol. 10, Iss. 3, 2015-05 ,pp. : 203-210

John Wiley & Sons Inc

Access to resources Recommend Favorite

Trends in the treatment of early‐stage Hodgkin lymphoma

CA: A CANCER JOURNAL FOR CLINICIANS, Vol. 65, Iss. 4, 2015-07 ,pp. : 253-254

John Wiley & Sons Inc

Access to resources Recommend Favorite

Surgical Treatment of Early-Stage Cervical Cancer

Oncology Research and Treatment, Vol. 39, Iss. 9, 2016-08 ,pp. : 508-514

Karger

Access to resources Recommend Favorite